Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
20 hedge funds and large institutions have $1.56M invested in Statera Biopharma, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 2 closing their positions.
425% more capital invested
Capital invested by funds: $298K → $1.56M (+$1.27M)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
11% more funds holding
Funds holding: 18 → 20 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$515K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$287K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$125K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$51.4K |
| 5 |
BlackRock
New York
|
+$37.1K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $569K | +$515K | +157,700 | +450% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $501K | +$287K | +87,885 | +107% |
|
|
LTFS
3
Ladenburg Thalmann Financial Services
Miami,
Florida
| $159K | – | – | – |
|
|
VKH
4
Virtu KCG Holdings
New York
| $154K | +$125K | +38,233 | +276% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $49K | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| $46K | +$51.4K | +15,718 | New |
|
|
7
BlackRock
New York
| $43K | +$37.1K | +11,356 | +321% |
|
|
TSS
8
Two Sigma Securities
New York
| $31K | +$34.3K | +10,495 | New |
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $6K | +$7.51K | +2,300 | +57,500% |
|
|
TDC
10
Thompson Davis & Co
Richmond,
Virginia
| $3K | +$3.27K | +1,000 | New |
|
|
IA
11
IFP Advisors
Tampa,
Florida
| $2K | – | – | – |
|
|
WA
12
Winfield Associates
Cleveland,
Ohio
| $1K | – | – | – |
|
|
BFEC
13
Benjamin F. Edwards & Company
St. Louis,
Missouri
| $1K | +$1.63K | +500 | New |
|
STAB Hedge Fund Activity: Q2 2017 in Review
20 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q2 2017, worth a combined $1.56M — up 425% from $298K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new STAB positions and 2 closed out — a net gain of 2 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $515K.
- 20 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q2 2017, up from 18 in Q1 2017.
- Funds reported $1.56M of Statera Biopharma, Inc. Common Stock stock for Q2 2017, up 425% quarter-over-quarter.
- 4 funds opened new Statera Biopharma, Inc. Common Stock positions in Q2 2017 and 2 closed out, a net change of +2 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q2 2017 was Renaissance Technologies, an estimated $515K added.
Based on aggregated 13F filings for Q2 2017.